Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.

Saved in:
Bibliographic Details
Title: Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Authors: Subbiah, Vivek1 (AUTHOR), Hu, Mimi I.2 (AUTHOR), Mansfield, Aaron S.3 (AUTHOR), Taylor, Matthew H.4 (AUTHOR), Schuler, Martin5 (AUTHOR), Zhu, Viola W.6 (AUTHOR), Hadoux, Julien7 (AUTHOR), Curigliano, Giuseppe8,9 (AUTHOR), Wirth, Lori10 (AUTHOR), Gainor, Justin F.10 (AUTHOR), Alonso, Guzman11 (AUTHOR), Adkins, Douglas12 (AUTHOR), Godbert, Yann13 (AUTHOR), Ahn, Myung-Ju14 (AUTHOR), Cassier, Philippe A.15 (AUTHOR), Cho, Byoung Chul16 (AUTHOR), Lin, Chia-Chi17 (AUTHOR), Zalutskaya, Alena18 (AUTHOR), Barata, Teresa19 (AUTHOR), Trask, Peter20 (AUTHOR)
Source: Thyroid. Jan2024, Vol. 34 Issue 1, p26-40. 15p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10507256
DOI:10.1089/thy.2023.0363